Core Viewpoint - FuboTV's stock experienced a significant decline of over 20% following the announcement of a reverse stock split, reflecting negative investor sentiment and concerns about financial distress [1] Financial Performance - Despite a headline loss in Q1, FuboTV's combined adjusted EBITDA has improved to nearly $78 million on a trailing-12-month pro forma basis, indicating operational improvements [3] - FuboTV's shares are currently trading at less than 0.4 times annual revenue, suggesting they are undervalued even for a struggling media company [4] Subscriber Base and Market Position - FuboTV has a total of 6.2 million subscribers in North America, maintaining its relevance in the pay television market with significant scale [4] Strategic Partnerships - The company has entered a landmark agreement to merge its sports-first streaming platform with Disney's Hulu and Live TV, which is expected to enhance cost-per-thousand impressions (CPM) and fill rates [5] - Expected synergies from the Disney deal are anticipated to begin realizing in the first quarter of 2026 [5] Investment Outlook - The extreme oversold conditions, combined with expected synergies from the Disney deal and improving operational metrics, present a tactical buying opportunity for risk-tolerant investors [6] - Wall Street analysts generally agree that the recent selloff of FuboTV shares has been excessive, with a consensus rating of "Hold" and a mean target price suggesting a potential upside of approximately 165% from current levels [7][9]

Group 1 - Cuentas, Inc. has extended the expiration date of its publicly traded warrants from February 4, 2026, to June 30, 2026, to encourage their exercise [1][4] - The warrants were originally issued on February 4, 2021, as part of a public offering, with a total of 2,790,697 units sold at $4.30 per unit, generating approximately $12.0 million in gross proceeds [2] - A reverse stock split occurred on March 24, 2023, at a ratio of 1-for-13, resulting in an increased exercise price of the warrants to $55.90 per share [3] Group 2 - The company plans to use the gross proceeds from the exercise of the warrants for working capital and general corporate purposes [4] - The company has restructured its business and entered into joint ventures with World Mobile, LLC and World Mobile Media Group, LLC [4] - The company has amended the Warrant Agency Agreement to allow the Board of Directors to reduce the exercise price of the warrants if market conditions are favorable [4]

Core Viewpoint - Adial Pharmaceuticals, Inc. will implement a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance its capital markets profile [1][3][4] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of each shareholder [2] - The reverse stock split will take effect on February 5, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis starting February 6, 2026 [1][2] - There will be no change to the total number of authorized shares as per the Company's Certificate of Incorporation [2] Group 2: Strategic Intentions - The reverse stock split aims to bring the Company into compliance with Nasdaq's minimum bid price requirement of at least $1.00 per share [3] - The action is expected to make the bid price more attractive to a wider range of institutional and retail investors [3][4] - The Company remains optimistic about its future and is focused on advancing its lead product, AD04, for the treatment of Alcohol Use Disorder [4][5] Group 3: Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders [5] - The lead investigational drug, AD04, is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder in heavy drinking patients [5] - The Company plans to conduct a new Phase 3 clinical trial program for AD04, which has shown promising results in reducing drinking without significant safety concerns [5]

Core Viewpoint - Adial Pharmaceuticals, Inc. is implementing a 1-for-25 reverse stock split to strengthen its capital markets profile and comply with Nasdaq's minimum bid price requirement [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of each shareholder [2]. - The reverse stock split will take effect on February 5, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis starting February 6, 2026 [1][2]. - There will be no change to the total number of authorized shares as per the Company's Certificate of Incorporation [2]. Group 2: Company Strategy and Future Outlook - The Company is optimistic about its future and is focused on advancing its lead product, AD04, a genetically targeted serotonin-3 receptor antagonist for treating Alcohol Use Disorder [3][4]. - Adial plans to conduct a new Phase 3 clinical trial program for AD04, targeting specific genotypes identified through its proprietary diagnostic genetic test [4]. - The Company believes that AD04 has the potential to treat other addictive disorders, including Opioid Use Disorder, gambling, and obesity [4].

Core Viewpoint - FuboTV Inc. reported a significant revenue increase in Q1 2026 but also faced a net loss, leading to a sharp decline in stock price and the announcement of a reverse stock split [1]. Financial Performance - FuboTV reported revenue of $1.543 billion for Q1 2026, representing a 40% increase compared to the same quarter the previous year [1]. - The company incurred a net loss of approximately $19.1 million for the quarter, with earnings per share reported at negative 2 cents [1]. Stock Market Reaction - Following the earnings report, FuboTV's stock price fell by 25%, trading around $1.71 per share [1]. Corporate Actions - FuboTV announced plans to initiate a reverse stock split, a less common corporate action compared to regular stock splits [1].

Core Insights - FuboTV Inc. reported Q1 2026 revenue of $1.543 billion, a 40% increase year-over-year, but also posted a net loss of approximately $19.1 million, resulting in negative earnings per share of 2 cents [1][2] - Following the earnings report, FuboTV's stock price dropped 25% to around $1.71 per share, indicating investor dissatisfaction with the net loss [3] - The company announced a reverse stock split, which is intended to make the stock more accessible to a broader base of investors and align the number of shares with the company's size and scope [4][7] Financial Performance - Revenue for Q1 2026 was $1.543 billion, reflecting a 40% increase from the previous year [1] - The net loss for the quarter was approximately $19.1 million, with earnings per share reported at negative 2 cents [2] Stock Market Reaction - FuboTV shares fell 25% to approximately $1.71 following the earnings announcement, indicating a significant market reaction to the reported net loss [3] Corporate Actions - The company announced a reverse stock split, which is a less common action compared to regular stock splits, aimed at making shares more appealing to investors [4][6] - The reverse stock split was approved by the board and is intended to better align the number of shares with the company's overall size and scope [7]

Core Viewpoint - Edible Garden AG Incorporated announced a planned reverse stock split of its common stock at a ratio of 1-for-10, effective February 3, 2026, to comply with Nasdaq's listing requirements and improve the trading profile of its shares [1][3]. Company Overview - Edible Garden is a leader in controlled environment agriculture (CEA), providing sustainable, locally grown organic produce through its innovative farming model, available in over 5,000 retail locations across the U.S., Caribbean, and South America [4]. - The company operates advanced vertically integrated greenhouses and processing facilities, including locations in Grand Rapids, Michigan, Webster City, Iowa, and Belvidere, New Jersey [4]. Reverse Stock Split Details - The reverse stock split was approved by stockholders on September 24, 2025, allowing the board to set the exact ratio within a range of 1-for-5 to 1-for-25, which was determined to be 1-for-10 [2]. - Post-split, the new CUSIP number will be 28059P501, with the par value per share remaining at $0.0001, and adjustments will be made to outstanding warrants and equity awards [2]. CEO Commentary - The CEO stated that the reverse stock split aims to maintain compliance with Nasdaq requirements and enhance the market perception of the company's shares while focusing on executing its business strategy [3]. Technology and Innovations - Edible Garden's proprietary GreenThumb 2.0 software optimizes greenhouse conditions and reduces food miles, while its patented Self-Watering display extends plant shelf life [5]. - The company holds patents in advanced aquaculture technologies, including a closed-loop shrimp farming system and a modular recirculating aquaculture setup [5]. Product Offerings - The company markets a range of nutrition and specialty food products, including plant and whey protein powders, and sustainable condiments [6].

Core Viewpoint - La Rosa Holdings Corp. will implement a 1-for-10 reverse stock split effective January 26, 2026, to reduce the number of outstanding shares and maintain compliance with Nasdaq listing requirements [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 10 shares of common stock into 1 share, reducing the total outstanding shares from approximately 5.35 million to about 535 thousand shares [2]. - The new CUSIP number for the common stock post-split will be 50172T301, and trading will continue under the symbol "LRHC" on a split-adjusted basis [2]. Group 2: Company Background and Business Model - La Rosa Holdings Corp. aims to transform the real estate industry by offering flexible compensation options for agents, including a revenue-sharing model and a fee-based structure with 100% commission [4]. - The company provides both residential and commercial real estate brokerage services, along with technology-driven products and support for agents and franchise partners [5]. - La Rosa operates 25 corporate-owned brokerage offices across several states and has begun expansion into Europe, starting with Spain [6].

Core Viewpoint - Psyence Biomedical Ltd. has decided to postpone the effective date of its previously announced reverse stock split of its common stock, which was initially set for January 20, 2026 [1][2]. Company Announcement - The Board of Directors had approved a reverse stock split at a ratio of 1-for-6.25, but after further internal consideration, the effectiveness of this split has been delayed to a later date [2]. - A subsequent press release will be issued, and required notifications will be filed with Nasdaq before establishing a new effective date for the reverse stock split [3]. Trading Information - Until a new effective date is established, the Company's common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "PBM" and its current CUSIP 74449F308 [3]. Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine-based medicines [4]. - The company aims to address unmet mental health needs and is committed to developing safe, effective, and FDA-approved nature-derived psychedelic treatments for various mental health disorders [4].

Core Viewpoint - Psyence Biomedical Ltd. has decided to postpone the effective date of its previously announced reverse stock split of its common stock, which was initially set for January 20, 2026 [1][2]. Group 1: Reverse Stock Split Details - The Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to take effect at the market opening on January 20, 2026 [2]. - The Company will issue a subsequent press release and file required notifications with Nasdaq before establishing a new effective date for the reverse stock split [3]. - Until a new effective date is set, the Company's common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "PBM" and its current CUSIP [3]. Group 2: Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics [4]. - It is the first life sciences biotechnology company focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq [4]. - The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for various mental health disorders [4].